|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Supplementary Table S2. Calculated variance inflation factors

|  |  |
| --- | --- |
|  | VIF |

|  |  |
| --- | --- |
| Category II / Category I | 2.347 |
| Category III / Category I | 2.364 |
| Category III / Category II | 1.788 |
| BMI | 1.065 |
| Fasting plasma glucose | 1.079 |
| Use of GLP‐1 receptor agonist | 2.433 |
| Use of DPP-4 inhibitor | 2.342 |
| Use of SGLT2 inhibitor | 1.353 |
| Number of concomitant antidiabetic drugs | 1.809 |

VIF: variance inflation factor, BMI: body mass index, GLP-1: glucagon-like peptide 1, DPP-4: dipeptidyl peptidase 4, SGLT2: sodium-glucose cotransporter 2. |